US 12,357,708

Application 18/820,804 · Granted Jul 15, 2025

Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

Estimated expiration

October 3, 2031

4y 317d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Oct 3, 2011
+ 20 years
Oct 3, 2031
PTA +0d
Oct 3, 2031
TD cap (US 10,064,959)
Oct 3, 2031
Final
Oct 3, 2031

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
August 30, 2024
Earliest effective filing
October 3, 2011
Issue date
July 15, 2025
PTA
0 days
Base expiry (before PTA)
October 3, 2031

October 3, 2011 + 20 years = October 3, 2031

  • Continuation of application 18/045,805, filed Oct 11, 2022, issued as US 12,496,358
  • Continuation of application 16/047,574, filed Jul 27, 2018
  • Continuation of application 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
  • Divisional of application 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
  • Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
  • Continuation of application 13/481,127, filed May 25, 2012
  • Continuation of application 13/251,840, filed Oct 3, 2011
  • Continuation of application 13/251,840, filed Oct 3, 2011
  • Continuation of application 13/481,127, filed May 25, 2012
  • Continuation of application 13/251,840, filed Oct 3, 2011
  • Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
  • Continuation of application 13/481,127, filed May 25, 2012
  • Continuation of application 13/251,840, filed Oct 3, 2011
  • Divisional of application 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
  • Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
  • Continuation of application 13/481,127, filed May 25, 2012
  • Continuation of application 13/251,840, filed Oct 3, 2011
  • Continuation of application 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
  • Divisional of application 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
  • Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
  • Continuation of application 13/481,127, filed May 25, 2012
  • Continuation of application 13/251,840, filed Oct 3, 2011
  • Continuation of application 16/047,574, filed Jul 27, 2018
  • Continuation of application 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
  • Divisional of application 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
  • Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
  • Continuation of application 13/481,127, filed May 25, 2012
  • Continuation of application 13/251,840, filed Oct 3, 2011
  • PRO61/404,413 — Provisional — not used for base term
  • PRO61/404,413 — Provisional — not used for base term
  • PRO61/404,413 — Provisional — not used for base term
  • PRO61/404,413 — Provisional — not used for base term
  • PRO61/404,413 — Provisional — not used for base term
  • PRO61/404,413 — Provisional — not used for base term
  • PRO61/404,413 — Provisional — not used for base term
  • PRO61/404,413 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to October 3, 2031 (earliest expiring referenced patent: US 10,064,959)

  • US 9,334,328· Application 13/739,212Capping patent

    Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

    Filing date
    Jan 11, 2013
    Earliest effective filing
    Oct 3, 2011
    Issue date
    May 10, 2016
    PTA
    +76 days
    Calculated expiration
    Dec 18, 2031

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/251,840, filed Oct 3, 2011

    Oct 3, 2011 + 20y + 76d PTA = Dec 18, 2031

  • US 10,064,959· Application 15/493,829Capping patent

    Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

    Filing date
    Apr 21, 2017
    Earliest effective filing
    Oct 3, 2011
    Issue date
    Sep 4, 2018
    PTA
    0 days
    Calculated expiration
    Oct 3, 2031

    Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Oct 3, 2011 + 20y = Oct 3, 2031

  • US 12,357,708· Application 18/820,804(from application 18/820,804)

    Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

    Filing date
    Aug 30, 2024
    Earliest effective filing
    Oct 3, 2011
    Issue date
    Jul 15, 2025
    PTA
    0 days
    Calculated expiration
    Oct 3, 2031

    Continuation of 18/045,805, filed Oct 11, 2022, issued as US 12,496,358

    Continuation of 16/047,574, filed Jul 27, 2018

    Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959

    Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959

    Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 16/047,574, filed Jul 27, 2018

    Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959

    Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Oct 3, 2011 + 20y = Oct 3, 2031

  • US 12,496,358· Application 18/045,805(from application 18/045,805)

    Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

    Filing date
    Oct 11, 2022
    Earliest effective filing
    Oct 3, 2011
    Issue date
    Dec 16, 2025
    PTA
    +399 days
    Calculated expiration
    Nov 5, 2032

    Continuation of 16/047,574, filed Jul 27, 2018

    Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959

    Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959

    Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295

    Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328

    Continuation of 13/481,127, filed May 25, 2012

    Continuation of 13/251,840, filed Oct 3, 2011

    Oct 3, 2011 + 20y + 399d PTA = Nov 5, 2032

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 18/820,804 · US 12,357,708

PatentReply compiles the prosecution history behind US 12,357,708: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12357708

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.